Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

NCT01730950 is registered in ClinicalTrials.gov with Radiation Therapy Oncology Group as lead sponsor.

NCT NCT01730950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01730950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Lead sponsor
Radiation Therapy Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
December 20, 2012
Completion date
December 22, 2022
Enrollment
182 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, recurrent adult brain tumor